
Professor Miraz Rahman
Professor of Medicinal Chemistry
Research interests
- Chemistry
Biography
Dr Miraz Rahman is a Professor of Medicinal Chemistry in School of Cancer & Pharmaceutical Sciences, King’s College London. After working three years in the industry, he went back to academia and obtained his PhD from the UCL School of Pharmacy in synthetic medicinal chemistry. His research activities are focused on the application of advanced computational chemistry, synthetic medicinal chemistry and chemical biology techniques to the design, synthesis and evaluation of novel drug-like chemical scaffolds as anticancer and anti-infective agents. He is the author of over 90 research publications, inventor on 15 patents and has more than 15 years research experience in medicinal chemistry and biophysical techniques. Dr Rahman has been working on pyrrolobenzodiazepine-based DNA binding agents for the past 16 years, and developed PBD-based anticancer and antibacterial agents that have been patented and licensed to university spin-out companies. He is working with Public Health England to develop chemical tools to study antimicrobial resistance (AMR) and discover new ways to target multiple drug-resistant pathogens. He has used a combination of homology modelling and advanced computational calculations to study bacterial and fungal efflux pumps and has invented new classes of efflux resistant antibiotics and antifungal agents that are currently being commercialised. The Rahman laboratory is located on the 5th floor of the Franklin Wilkins Building at King’s College London and is funded by grants from industry, charities and research councils. He has experience in early and late-stage drug discovery, and translational research, co-founding oncology biotech companies Transcriptogen Ltd (2013) and Femtogenix Ltd (2015).
Research

Drug Discovery
The Drug Discovery Group brings together scientific expertise in a broad range of areas, from medicinal chemistry to systems biology and pharmacology.

Antimicrobial Research Theme
Antimicrobial Research Theme
News
IPS colleagues win major awards at international PharmSci conference
The awards included the Academy of Pharmaceutical Sciences' (APS) Science and Emerging Scientist awards alongside multiple invited podiums and poster...

King's biotech spinout re-launches with new name and $68 million funding
Pheon Therapeutics, which has its origins in research carried out in the Institute of Pharmaceutical Sciences (IPS), launched on Wednesday 28 September based...

Six new Studentships for Institute of Pharmaceutical Science
The School of Cancer & Pharmaceutical Science are pleased to announce that there are six new studentships within the Institute of Pharmaceutical Sciences.

New broad-spectrum antibiotic class identified
Researchers from the School of Cancer & Pharmaceutical Sciences have discovered a new broad-spectrum antibiotic class with activity against...

5 minutes with Miraz Rahman
Miraz Rahman is a Reader in Medicinal Chemistry in the School of Cancer & Pharmaceutical Sciences. We took 5 minutes with Miraz to learn more about his career...

Events

Inaugural Lecture: Professors Pablo Lamata & Miraz Rahman
Inspiring talks from some of our brightest minds
Please note: this event has passed.
Spotlight
How King's continues to tackle cancer and support cancer care and research
Saturday 4 February marks World Cancer Day. In order to honour this key date, we have highlighted some of the most important cancer-themed stories that have...

Spotlight on COVID: Searching for therapeutics
Dr Miraz Rahman discusses research aiming to find new therapeutics to treat COVID

Research

Drug Discovery
The Drug Discovery Group brings together scientific expertise in a broad range of areas, from medicinal chemistry to systems biology and pharmacology.

Antimicrobial Research Theme
Antimicrobial Research Theme
News
IPS colleagues win major awards at international PharmSci conference
The awards included the Academy of Pharmaceutical Sciences' (APS) Science and Emerging Scientist awards alongside multiple invited podiums and poster...

King's biotech spinout re-launches with new name and $68 million funding
Pheon Therapeutics, which has its origins in research carried out in the Institute of Pharmaceutical Sciences (IPS), launched on Wednesday 28 September based...

Six new Studentships for Institute of Pharmaceutical Science
The School of Cancer & Pharmaceutical Science are pleased to announce that there are six new studentships within the Institute of Pharmaceutical Sciences.

New broad-spectrum antibiotic class identified
Researchers from the School of Cancer & Pharmaceutical Sciences have discovered a new broad-spectrum antibiotic class with activity against...

5 minutes with Miraz Rahman
Miraz Rahman is a Reader in Medicinal Chemistry in the School of Cancer & Pharmaceutical Sciences. We took 5 minutes with Miraz to learn more about his career...

Events

Inaugural Lecture: Professors Pablo Lamata & Miraz Rahman
Inspiring talks from some of our brightest minds
Please note: this event has passed.
Spotlight
How King's continues to tackle cancer and support cancer care and research
Saturday 4 February marks World Cancer Day. In order to honour this key date, we have highlighted some of the most important cancer-themed stories that have...

Spotlight on COVID: Searching for therapeutics
Dr Miraz Rahman discusses research aiming to find new therapeutics to treat COVID
